This new license is an important step forward in bringing a new drug therapy closer to patients living with diabetes as it will enable us to access a promising lead drug candidate and position us to start clinical trials as early as 2018. VANCOUVER and TORONTO, Canada (October 14, 2016) — Zucara Therapeutics Inc., a […]
VANCOUVER and TORONTO, Canada (September 9, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has appointed Michael Midmer as its Chief Executive Officer. Midmer has over 15 years of experience in the life sciences, fund management and corporate finance. He […]
The World Health Organization (WHO) has marked April 7, 2016 as World Health Day. The focus of this year’s theme is diabetes. The number of people living with diabetes has almost quadrupled since 1980 to 422 million adults and this number likely to more than double in the next 20 years. For more information on the global call […]
VANCOUVER, BC (February 2, 2016) — The Centre for Drug Research and Development (CDRD) announced today that two of its spin-off companies, Zucara Therapeutics and Sepset Biosciences, have been chosen to present at “Dose of the Valley” in San Francisco on February 9 and 10, 2016. Dose of the Valley is a two-day program organized by the […]
TORONTO and VANCOUVER, CANADA (January 12, 2016) — A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being developed by Zucara Therapeutics Inc. This new start-up company, created by MaRS Innovation and The Centre for Drug Research and Development (CDRD) is based on […]